Markianos M, Hadjikonstantinou M, Sfagos C
Acta Neurol Scand. 1981 Apr;63(4):267-72. doi: 10.1111/j.1600-0404.1981.tb00780.x.
Plasma dopamine-beta-hydroxylase activity (DBH) was estimated in 50 drug-free Parkinson patients, 30 of whom had never been treated, in 26 patients treated chronically with L-Dopa, and in 44 controls. 22 of the drug-free patients were examined again after two weeks treatment with L-Dopa plus decarboxylase inhibitor. In disagreement with other reports, no differences were found among the groups and no change in the enzyme activity occurred after treatment, although urinary homovanillic acid increased 20 fold. Low DBH activities could not be attributed to the age of onset or duration of illness, main symptom, depression, autonomic disturbances, or duration of drug treatment. The only difference was found in patients with dementia associated to their illness, who showed low enzyme activities.
对50例未服用药物的帕金森病患者、其中30例从未接受过治疗的患者、26例长期接受左旋多巴治疗的患者以及44名对照者进行了血浆多巴胺-β-羟化酶活性（DBH）评估。22例未服用药物的患者在接受左旋多巴加脱羧酶抑制剂治疗两周后再次接受检查。与其他报告不同的是，各组之间未发现差异，治疗后酶活性也未发生变化，尽管尿高香草酸增加了20倍。低DBH活性不能归因于发病年龄、病程、主要症状、抑郁、自主神经紊乱或药物治疗时间。唯一的差异发现于患有与其疾病相关痴呆的患者，这些患者酶活性较低。
